Adam R Burr1, H Ian Robins1, R Adam Bayliss1, Steven P Howard2. 1. Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Carbone Cancer Center, Madison, Wisconsin. 2. Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Carbone Cancer Center, Madison, Wisconsin. Electronic address: howard@humonc.wisc.edu.
Abstract
PURPOSE: Locoregionally recurrent breast cancer within a previously irradiated field requires weighing the benefits of reirradiation against the increased rates of toxicity. Here we evaluate the outcomes of patients treated with pulsed reduced dose rate (PRDR) radiation therapy with concurrent low-dose capecitabine as a method to increase the therapeutic ratio of re-treatment. METHODS AND MATERIALS: Patients treated from November 2000 to June 1, 2018 with PRDR radiation therapy at University of Wisconsin were identified. Patients were re-treated to a median dose of 54 Gy (range, 37.5-66 Gy) using PRDR radiation therapy, delivering radiation at an apparent dose rate of 6.67 cGy/min to allow for increased sublethal damage repair of normal tissues. The median cumulative dose was 109.8 Gy. Twenty-two patients were treated with concurrent capecitabine, most frequently at 500 mg twice per day. The Kaplan-Meier method was used for survival analysis, and Cox regression analysis was used for univariate and multivariate analysis. RESULTS: Forty-three patients were identified who underwent reirradiation for locoregionally recurrent invasive breast cancer, with a median follow-up of 20.5 months. Twenty-four patients had gross disease. Nineteen patients had simultaneous metastatic disease. The complete response rate was 83.3% in treated patients with gross disease. Locoregional recurrence-free survival was 81.3% and 73.8% for all patients at 1 and 2 years, respectively. Overall survival for patients with localized disease was 95.7% at 1 year and 91.1% at 2 years. The rate of acute grade 3 radiation dermatitis was 25.6% with no other acute grade 3 toxicities. Grade 3 late toxicity occurred in 18.6% of patients. CONCLUSIONS: PRDR radiation therapy with capecitabine was a well-tolerated and effective method for treating patients with recurrent breast cancer. Prospective studies are necessary to compare side effects and efficacy with conventional dose rate reirradiation and to evaluate the potential role for capecitabine in the recurrent setting. Published by Elsevier Inc.
PURPOSE: Locoregionally recurrent breast cancer within a previously irradiated field requires weighing the benefits of reirradiation against the increased rates of toxicity. Here we evaluate the outcomes of patients treated with pulsed reduced dose rate (PRDR) radiation therapy with concurrent low-dose capecitabine as a method to increase the therapeutic ratio of re-treatment. METHODS AND MATERIALS: Patients treated from November 2000 to June 1, 2018 with PRDR radiation therapy at University of Wisconsin were identified. Patients were re-treated to a median dose of 54 Gy (range, 37.5-66 Gy) using PRDR radiation therapy, delivering radiation at an apparent dose rate of 6.67 cGy/min to allow for increased sublethal damage repair of normal tissues. The median cumulative dose was 109.8 Gy. Twenty-two patients were treated with concurrent capecitabine, most frequently at 500 mg twice per day. The Kaplan-Meier method was used for survival analysis, and Cox regression analysis was used for univariate and multivariate analysis. RESULTS: Forty-three patients were identified who underwent reirradiation for locoregionally recurrent invasive breast cancer, with a median follow-up of 20.5 months. Twenty-four patients had gross disease. Nineteen patients had simultaneous metastatic disease. The complete response rate was 83.3% in treated patients with gross disease. Locoregional recurrence-free survival was 81.3% and 73.8% for all patients at 1 and 2 years, respectively. Overall survival for patients with localized disease was 95.7% at 1 year and 91.1% at 2 years. The rate of acute grade 3 radiation dermatitis was 25.6% with no other acute grade 3 toxicities. Grade 3 late toxicity occurred in 18.6% of patients. CONCLUSIONS: PRDR radiation therapy with capecitabine was a well-tolerated and effective method for treating patients with recurrent breast cancer. Prospective studies are necessary to compare side effects and efficacy with conventional dose rate reirradiation and to evaluate the potential role for capecitabine in the recurrent setting. Published by Elsevier Inc.
Authors: Ishita Chen; Astrid M Botty Van den Bruele; Erin F Gillespie; Boris A Mueller; Amy J Xu; John Cuaron; Atif J Khan; Beryl McCormick; Oren Cahlon; Simon N Powell; Hiram Cody; Lior Z Braunstein Journal: Breast Cancer Res Treat Date: 2021-03-26 Impact factor: 4.872
Authors: Tugce Kutuk; Ranjini Tolakanahalli; Nicole C McAllister; Matthew D Hall; Martin C Tom; Muni Rubens; Haley Appel; Alonso N Gutierrez; Yazmin Odia; Alexander Mohler; Manmeet S Ahluwalia; Minesh P Mehta; Rupesh Kotecha Journal: Cancers (Basel) Date: 2022-06-15 Impact factor: 6.575
Authors: Adam R Burr; Henry Ian Robins; Robert Adam Bayliss; Andrew M Baschnagel; James S Welsh; Wolfgang A Tomé; Steven P Howard Journal: Adv Radiat Oncol Date: 2020-07-08
Authors: Muayad F Almahariq; Thomas J Quinn; Jessica D Arden; P T Roskos; George D Wilson; Brian Marples; Inga S Grills; Peter Y Chen; Daniel J Krauss; Prakash Chinnaiyan; Joshua T Dilworth Journal: Neuro Oncol Date: 2021-03-25 Impact factor: 12.300
Authors: Zuhair D Hammood; Abdulwahid M Salih; Snur Othman; Berwn A Abdulla; Shvan H Mohammed; Fahmi H Kakamad; Sharo Naqar Journal: Int J Surg Case Rep Date: 2022-02-12